PRAME and acute myeloid leukemia: AML cell lines were used to show that PRAME is involved in retinoic acid-regulated (RAR) cell proliferation and differentiation by inhibiting RAR signalling [111] and introducing all-trans-retinoic acid (ATRA) may be able to reverse this, especially in patients without the t(15:17) mutation.